Rarity support Elicera Therapeutics in cutting edge CAR-T therapy study

June 7, 2022
car-t white paper
On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells.
“The assay from Rarity shows similar or better CV than current available ddPCR assays, and a much more cost efficient alternative. Based on the sensitivity and robustness of Rarity’s technique, we hope to use this technique for detecting CAR-T cell persistence during patient follow-up” – Di Yu, Co-founder of Elicera & Head of Translational Research & Technical Operations
Click on the image to enlarge, and read the full white paper.